Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 7 of 7 entries
Sorted by: Best Match Show Resources per page
Investigation of the Physicochemical and Biological Stability of the Adalimumab Biosimilar CT-P17.

Advances in therapy

Shin YK, Han WY, Kim SJ, Kim KW, Roh JW, Lee JB, Oh JS, Astier A.
PMID: 34618346
Adv Ther. 2021 Nov;38(11):5609-5622. doi: 10.1007/s12325-021-01929-x. Epub 2021 Oct 07.

INTRODUCTION: CT-P17 (Celltrion, Inc., Incheon, Republic of Korea) is a biosimilar of reference adalimumab (HumiraMETHODS: This analysis was designed to evaluate the stability profile of CT-P17 compared with reference adalimumab and the currently licensed adalimumab biosimilars ABP 501 (AmjevitaRESULTS:...

Cite
Shin YK, Han WY, Kim SJ, et al. Investigation of the Physicochemical and Biological Stability of the Adalimumab Biosimilar CT-P17. Adv Ther. 2021;38(11):5609-5622doi: 10.1007/s12325-021-01929-x.
Shin, Y. K., Han, W. Y., Kim, S. J., Kim, K. W., Roh, J. W., Lee, J. B., Oh, J. S., & Astier, A. (2021). Investigation of the Physicochemical and Biological Stability of the Adalimumab Biosimilar CT-P17. Advances in therapy, 38(11), 5609-5622. https://doi.org/10.1007/s12325-021-01929-x
Shin, Yeon Kyeong, et al. "Investigation of the Physicochemical and Biological Stability of the Adalimumab Biosimilar CT-P17." Advances in therapy vol. 38,11 (2021): 5609-5622. doi: https://doi.org/10.1007/s12325-021-01929-x
Shin YK, Han WY, Kim SJ, Kim KW, Roh JW, Lee JB, Oh JS, Astier A. Investigation of the Physicochemical and Biological Stability of the Adalimumab Biosimilar CT-P17. Adv Ther. 2021 Nov;38(11):5609-5622. doi: 10.1007/s12325-021-01929-x. Epub 2021 Oct 07. PMID: 34618346.
Copy Download .nbib Format: NLM
Evaluation of similar quality attribute characteristics in SB5 and reference product of adalimumab.

mAbs

Lee N, Lee JJ, Yang H, Baek S, Kim S, Kim S, Lee T, Song D, Park G.
PMID: 30296198
MAbs. 2019 Jan;11(1):129-144. doi: 10.1080/19420862.2018.1530920. Epub 2018 Oct 19.

Biosimilars are biologic products that are highly similar to a licensed reference product in terms of quality, safety, and efficacy. SB5 is a biosimilar of Humira® (adalimumab) developed by Samsung Bioepis. To demonstrate its biosimilarity in quality to Humira®,...

Cite
Lee N, Lee JJ, Yang H, et al. Evaluation of similar quality attribute characteristics in SB5 and reference product of adalimumab. MAbs. 2018;11(1):129-144doi: 10.1080/19420862.2018.1530920.
Lee, N., Lee, J. J., Yang, H., Baek, S., Kim, S., Kim, S., Lee, T., Song, D., & Park, G. (2019). Evaluation of similar quality attribute characteristics in SB5 and reference product of adalimumab. mAbs, 11(1), 129-144. https://doi.org/10.1080/19420862.2018.1530920
Lee, Nayoung, et al. "Evaluation of similar quality attribute characteristics in SB5 and reference product of adalimumab." mAbs vol. 11,1 (2019): 129-144. doi: https://doi.org/10.1080/19420862.2018.1530920
Lee N, Lee JJ, Yang H, Baek S, Kim S, Kim S, Lee T, Song D, Park G. Evaluation of similar quality attribute characteristics in SB5 and reference product of adalimumab. MAbs. 2019 Jan;11(1):129-144. doi: 10.1080/19420862.2018.1530920. Epub 2018 Oct 19. PMID: 30296198; PMCID: PMC6343792.
Copy Download .nbib Format: NLM
Comparison of consistency and complementarity of reporting biosimilar quality attributes between regulatory and scientific communities: An adalimumab case study.

Biologicals : journal of the International Association of Biological Standardization

Alsamil AM, Giezen TJ, Egberts TC, Leufkens HG, Gardarsdottir H.
PMID: 33454195
Biologicals. 2021 Jan;69:30-37. doi: 10.1016/j.biologicals.2020.12.003. Epub 2021 Jan 13.

Biosimilar approval relies on the comparability of quality attributes (QAs), for which information can be derived from regulatory or scientific communities. Limited information is known about whether these sources are consistent with or complementary to each other. The consistency...

Cite
Alsamil AM, Giezen TJ, Egberts TC, et al. Comparison of consistency and complementarity of reporting biosimilar quality attributes between regulatory and scientific communities: An adalimumab case study. Biologicals. 2021;69:30-37doi: 10.1016/j.biologicals.2020.12.003.
Alsamil, A. M., Giezen, T. J., Egberts, T. C., Leufkens, H. G., & Gardarsdottir, H. (2021). Comparison of consistency and complementarity of reporting biosimilar quality attributes between regulatory and scientific communities: An adalimumab case study. Biologicals : journal of the International Association of Biological Standardization, 6930-37. https://doi.org/10.1016/j.biologicals.2020.12.003
Alsamil, Ali M, et al. "Comparison of consistency and complementarity of reporting biosimilar quality attributes between regulatory and scientific communities: An adalimumab case study." Biologicals : journal of the International Association of Biological Standardization vol. 69 (2021): 30-37. doi: https://doi.org/10.1016/j.biologicals.2020.12.003
Alsamil AM, Giezen TJ, Egberts TC, Leufkens HG, Gardarsdottir H. Comparison of consistency and complementarity of reporting biosimilar quality attributes between regulatory and scientific communities: An adalimumab case study. Biologicals. 2021 Jan;69:30-37. doi: 10.1016/j.biologicals.2020.12.003. Epub 2021 Jan 13. PMID: 33454195.
Copy Download .nbib Format: NLM
Mining Potential Effects of HUMIRA in Twitter Posts Through Relational Similarity.

Studies in health technology and informatics

Jiang K, Feng S, Huang L, Chen T, Bernard GR.
PMID: 32570507
Stud Health Technol Inform. 2020 Jun 16;270:874-878. doi: 10.3233/SHTI200286.

HUMIRA, a biologic therapy, has been approved to treat autoimmune diseases and been marketed in many countries worldwide. Much like other medications, it demonstrates many effects on the human body. It is important to understand its effects from the...

Cite
Jiang K, Feng S, Huang L, et al. Mining Potential Effects of HUMIRA in Twitter Posts Through Relational Similarity. Stud Health Technol Inform. 2020;270:874-878doi: 10.3233/SHTI200286.
Jiang, K., Feng, S., Huang, L., Chen, T., & Bernard, G. R. (2020). Mining Potential Effects of HUMIRA in Twitter Posts Through Relational Similarity. Studies in health technology and informatics, 270874-878. https://doi.org/10.3233/SHTI200286
Jiang, Keyuan, et al. "Mining Potential Effects of HUMIRA in Twitter Posts Through Relational Similarity." Studies in health technology and informatics vol. 270 (2020): 874-878. doi: https://doi.org/10.3233/SHTI200286
Jiang K, Feng S, Huang L, Chen T, Bernard GR. Mining Potential Effects of HUMIRA in Twitter Posts Through Relational Similarity. Stud Health Technol Inform. 2020 Jun 16;270:874-878. doi: 10.3233/SHTI200286. PMID: 32570507.
Copy Download .nbib Format: NLM
Overview of Humira® Biosimilars: Current European Landscape and Future Implications.

Journal of pharmaceutical sciences

Coghlan J, He H, Schwendeman AS.
PMID: 33556387
J Pharm Sci. 2021 Apr;110(4):1572-1582. doi: 10.1016/j.xphs.2021.02.003. Epub 2021 Feb 05.

Humira® (adalimumab) by AbbVie has been the top-selling biologic drug product for the last few years - reaching nearly $20 billion in annual sales in 2018. Upon the October 2018 release of four adalimumab biosimilars into the European market,...

Cite
Coghlan J, He H, Schwendeman AS. Overview of Humira® Biosimilars: Current European Landscape and Future Implications. J Pharm Sci. 2021;110(4):1572-1582doi: 10.1016/j.xphs.2021.02.003.
Coghlan, J., He, H., & Schwendeman, A. S. (2021). Overview of Humira® Biosimilars: Current European Landscape and Future Implications. Journal of pharmaceutical sciences, 110(4), 1572-1582. https://doi.org/10.1016/j.xphs.2021.02.003
Coghlan, Jill, et al. "Overview of Humira® Biosimilars: Current European Landscape and Future Implications." Journal of pharmaceutical sciences vol. 110,4 (2021): 1572-1582. doi: https://doi.org/10.1016/j.xphs.2021.02.003
Coghlan J, He H, Schwendeman AS. Overview of Humira® Biosimilars: Current European Landscape and Future Implications. J Pharm Sci. 2021 Apr;110(4):1572-1582. doi: 10.1016/j.xphs.2021.02.003. Epub 2021 Feb 05. PMID: 33556387; PMCID: PMC8014989.
Copy Download .nbib Format: NLM
Effectiveness and safety of switching to adalimumab biosimilar ABP 501 in Crohn's disease: the extrapolation concept.

Revista espanola de enfermedades digestivas : organo oficial de la Sociedad Espanola de Patologia Digestiva

Ribaldone DG, Vernero M, Astegiano M.
PMID: 33207912
Rev Esp Enferm Dig. 2021 Feb;113(2):155. doi: 10.17235/reed.2020.7253/2020.

We sincerely thank Viscido et al. for their appropriate and sharable comments on our recent study on adalimumab biosimilar ABP 501 in Crohn's disease (CD). The use of a biosimilar in inflammatory disorders is one of the current main...

Cite
Ribaldone DG, Vernero M, Astegiano M. Effectiveness and safety of switching to adalimumab biosimilar ABP 501 in Crohn's disease: the extrapolation concept. Rev Esp Enferm Dig. 2021;113(2):155doi: 10.17235/reed.2020.7253/2020.
Ribaldone, D. G., Vernero, M., & Astegiano, M. (2021). Effectiveness and safety of switching to adalimumab biosimilar ABP 501 in Crohn's disease: the extrapolation concept. Revista espanola de enfermedades digestivas : organo oficial de la Sociedad Espanola de Patologia Digestiva, 113(2), 155. https://doi.org/10.17235/reed.2020.7253/2020
Ribaldone, Davide Giuseppe, et al. "Effectiveness and safety of switching to adalimumab biosimilar ABP 501 in Crohn's disease: the extrapolation concept." Revista espanola de enfermedades digestivas : organo oficial de la Sociedad Espanola de Patologia Digestiva vol. 113,2 (2021): 155. doi: https://doi.org/10.17235/reed.2020.7253/2020
Ribaldone DG, Vernero M, Astegiano M. Effectiveness and safety of switching to adalimumab biosimilar ABP 501 in Crohn's disease: the extrapolation concept. Rev Esp Enferm Dig. 2021 Feb;113(2):155. doi: 10.17235/reed.2020.7253/2020. PMID: 33207912.
Copy Download .nbib Format: NLM
Comprehensive characterisation of the heterogeneity of adalimumab via charge variant analysis hyphenated on-line to native high resolution Orbitrap mass spectrometry.

mAbs

Füssl F, Trappe A, Cook K, Scheffler K, Fitzgerald O, Bones J.
PMID: 30296204
MAbs. 2019 Jan;11(1):116-128. doi: 10.1080/19420862.2018.1531664. Epub 2018 Nov 11.

Charge variant analysis is a widely used tool to monitor changes in product quality during the manufacturing process of monoclonal antibodies (mAbs). Although it is a powerful technique for revealing mAb heterogeneity, an unexpected outcome, for example the appearance...

Cite
Füssl F, Trappe A, Cook K, et al. Comprehensive characterisation of the heterogeneity of adalimumab via charge variant analysis hyphenated on-line to native high resolution Orbitrap mass spectrometry. MAbs. 2018;11(1):116-128doi: 10.1080/19420862.2018.1531664.
Füssl, F., Trappe, A., Cook, K., Scheffler, K., Fitzgerald, O., & Bones, J. (2019). Comprehensive characterisation of the heterogeneity of adalimumab via charge variant analysis hyphenated on-line to native high resolution Orbitrap mass spectrometry. mAbs, 11(1), 116-128. https://doi.org/10.1080/19420862.2018.1531664
Füssl, Florian, et al. "Comprehensive characterisation of the heterogeneity of adalimumab via charge variant analysis hyphenated on-line to native high resolution Orbitrap mass spectrometry." mAbs vol. 11,1 (2019): 116-128. doi: https://doi.org/10.1080/19420862.2018.1531664
Füssl F, Trappe A, Cook K, Scheffler K, Fitzgerald O, Bones J. Comprehensive characterisation of the heterogeneity of adalimumab via charge variant analysis hyphenated on-line to native high resolution Orbitrap mass spectrometry. MAbs. 2019 Jan;11(1):116-128. doi: 10.1080/19420862.2018.1531664. Epub 2018 Nov 11. PMID: 30296204; PMCID: PMC6343805.
Copy Download .nbib Format: NLM
Showing 1 to 7 of 7 entries